NetworkNewsBreaks – Evoke Pharma, Inc. (NASDAQ: EVOK) Shares Surge on Positive Data from Phase 3 Gimoti Study
Shares of Evoke Pharma (NASDAQ: EVOK) are 35% higher in morning trade after the company reported positive data from its phase 3 trial of Gimoti for symptomatic relief of acute and recurrent diabetic gastroparesis. While the study failed to reach its primary endpoint, Gimoti “significantly” reduced nausea and abdominal pain in moderate to severe patients. Evoke notes that the results are consistent with FDA guidance on the clinical evaluation of drugs used to treat gastroparesis. “As our discussions with the FDA progressed over the past few months, we have continued to analyze data from our Phase 3 trial of Gimoti…